Risperidone
- Generic Name
- Risperidone
- Brand Names
- Perseris, Risperdal, Rykindo, Uzedy, Okedi
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27FN4O2
- CAS Number
- 106266-06-2
- Unique Ingredient Identifier
- L6UH7ZF8HC
- Background
Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).
...
- Indication
Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.
...
- Associated Conditions
- Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state
- Associated Therapies
- -
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
- Conditions
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2011-06-08
- Target Recruit Count
- 381
- Registration Number
- NCT00246285
A Randomized, Open-label Trial of Long-acting Injectable Risperidone Versus Oral Antipsychotic Medication in Patients With Bipolar Disorder
- Conditions
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- Janssen-Ortho Inc., Canada
- Target Recruit Count
- 48
- Registration Number
- NCT00246246
An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone
- Conditions
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2010-04-27
- Lead Sponsor
- Janssen-Ortho Inc., Canada
- Target Recruit Count
- 82
- Registration Number
- NCT00246272
Side Effects of Newer Antipsychotics in Older Adults
- Conditions
- Interventions
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- Veterans Medical Research Foundation
- Target Recruit Count
- 406
- Registration Number
- NCT00245206
- Locations
- 🇺🇸
University of California, San Diego, San Diego, California, United States
A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 205
- Registration Number
- NCT00240708
A Study of the Safety of Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-06-08
- Target Recruit Count
- 232
- Registration Number
- NCT00236470
Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen, LP
- Target Recruit Count
- 86
- Registration Number
- NCT00236353
A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-06-08
- Target Recruit Count
- 629
- Registration Number
- NCT00236457
A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-06-08
- Target Recruit Count
- 375
- Registration Number
- NCT00236444
A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-06-08
- Target Recruit Count
- 100
- Registration Number
- NCT00236587
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.